SkylineDx at the forefront of a genomic revolution
SkylineDx is dedicated to optimize therapeutic decision making through the development of molecular diagnostic tests for blood cancers and thereby improving the quality of life of blood cancer patients.Discover more
Learn more about MMprofiler™, the lead product of SkylineDx. It is a prognostic test to determine the level of risk of a multiple myeloma patient by classifying such patient into a “high” or “standard” risk group with the use of the novel SKY92 gene signature.Learn more
08 Sep 2015
SKY92-ISS Superior to current markers in risk classification for myeloma survival
Article in Blood shows the reliability of SKY92 genetic subtyping signature for prediction of disease progress for multiple myeloma (bone marrow cancer) patients Rotterdam, the Netherlands, 8 September 2015 – Researchers at the Erasmus M...
02 Nov 2015 - 04 Nov 2015, Munich, Germany
14 Nov 2015 - 14 Nov 2015, Charlotte, NC USA
1st Annual Levine Cancer Institute Hematologic Malignancies Update
05 Dec 2015 - 08 Dec 2015, Orlando, FL USA
American Society of Hematology Annual Meeting. Visit us at booth 867.
A short video introducing SkylineDx’s new molecular prognostic test for multiple myeloma (MM): the MMprofiler.
SkylineDx is a pioneer in the field of molecular diagnostics through developing and commercializing innovative, signature-based diagnostics with a high clinical value that help to provide physicians and patients with the best individual care possible.